CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab

Percentage of Participants on TCZ Treatment at Month 6

Percentage of Participants by TCZ Dose at Month 6

Percentage of Participants Starting TCZ After Inadequate Response (IR) to a Biologic Treatment or After Intolerance or IR to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Time Elapsed From Diagnosis of RA

Patient Assessment of Pain Using Visual Analog Scale (VAS) at Baseline

Patient Global Assessment of Disease Activity (PGH) Using VAS at Baseline

Physician Global Assessment of Disease Activity (PhGH) Using VAS at Baseline

Participant Assessment of Morning Stiffness Using VAS at Baseline

Participant Assessment of Fatigue Using VAS at Baseline

Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Baseline

Tender Joint Count (TJC) at Baseline

Swollen Joint Count (SJC) at Baseline

Erythrocyte Sedimentation Rate (ESR) at Baseline

C-Reactive Protein (CRP) at Baseline

Percentage of Participants With Presence of Extra-Articular Systemic Features of RA at Baseline

Percentage of Participants With Evidence of Structural Joint Damage at Baseline

Percentage of Participants With Previous RA-Related Surgical Procedures at Baseline

Percentage of Participants With Positive Rheumatoid Factor (RF) at Baseline

Percentage of Participants With Anti-Citrullinated Cyclic Peptide at Baseline

Percentage of Participants by Duration of Morning Stiffness at Baseline

Number of Participants With TCZ Dose Change According to the Reason for Change

Percentage of Participants by Number of TCZ Dose Modifications Per Participant

Time in Days Elapsed Between TCZ Infusions

Percentage of Participants With TCZ Infusion Interruption

Percentage of Participants Who Discontinued TCZ by Reason for Discontinuation

Percentage of Participants With TCZ Reintroduction

Percentage of Participants by Reason for Choice of TCZ Monotherapy at Baseline

Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) Score at Month 3 and Month 6

Change From Baseline in Simplified Disease Activity Index (SDAI) Score at Month 3 and Month 6

Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Month 3 and Month 6

Percentage of Participants by DAS28 Class at the Start of TCZ Treatment and After Month 3 and Month 6

Percentage of Participants by SDAI Class at the Start of TCZ Treatment and After Month 3 and Month 6

Percentage of Participants by CDAI Class at the Start of TCZ Treatment and After Month 3 and Month 6

Percentage of Participants With an American College of Rheumatology (ACR) 20%, 50%, 70%, or 90% (ACR20/50/70/90) Response After Month 3 and Month 6 From the Start of TCZ Treatment

Change From Baseline to Month 6 in TJC

Change From Baseline to Month 6 in SJC

Change From Baseline to Month 6 in PGH

Change From Baseline to Month 6 in PhGH

Change From Baseline to Month 6 in Patient's Assessment of Pain

Change From Baseline to Month 6 in HAQ-DI Score

Change From Baseline to Month 6 in Participant Assessment of Fatigue

Change From Baseline to Month 6 in Participant Assessment of Morning Stiffness

Percentage of Participants With Clinically Meaningful Improvement in HAQ-DI

Percentage of Participants Achieving Good/Moderate/No European League Against Rheumatism (EULAR) Response at Month 3 and Month 6

Time to DMARD Dose Reduction

Time to DMARD Dose Withdrawal

Percentage of Participants by Reason for DMARD Withdrawal During the Study

Time to Steroid Dose Reduction

Time to Steroid Dose Withdrawal

Change From Baseline in CRP at Month 3 and Month 6

Change From Baseline in ESR at Month 3 and Month 6

CRP at the Start of TCZ Treatment by Remission Status Using DAS28-CRP, SDAI, and CDAI at Month 6

Body Mass Index (BMI) at the Start of TCZ Treatment by Remission Status Using DAS-28 CRP, SDAI, and CDAI at Month 6

Percentage of Participants With and Without Morning Stiffness

Percentage of Participants by Duration of Morning Stiffness

CRP at the Start of TCZ Treatment by Morning Stiffness at Month 6

BMI at the Start of TCZ Treatment by Morning Stiffness at Month 6

Correlation Coefficient Between CRP (mg/dL) at the Start of TCZ Treatment and HAQ-DI (0-3) at Month 6

Correlation Coefficient Between Change From Baseline in CRP (mg/dL) and HAQ-DI (0-3) at Month 6

Correlation Coefficient Between CRP (mg/dL) at the Start of TCZ Treatment and VAS Fatigue at Month 6

Correlation Coefficient Between Change From Baseline in CRP (mg/dL) at the Start of TCZ Treatment and Change From Baseline in VAS Fatigue at Month 6

Correlation Coefficient Between BMI at the Start of TCZ Treatment and HAQ-DI (0-3) at Month 6

Correlation Coefficient Between Change From Baseline in CRP (mg/dL) and Change From Baseline in Morning Stiffness According to VAS at Month 6

Correlation Coefficient Between BMI at the Start of TCZ Treatment and VAS Fatigue at Month 6